Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Vanda Pharmaceuticals (VNDA) PT Raised to $13 at Cantor Fitzgerald
August 1, 2024 6:35 AM EDTCantor Fitzgerald analyst Charles Duncan raised the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $13.00 (from $11.00) while maintaining a Overweight rating.
The analyst comments "Overall, we see VNDA as a differentiated Neuro-Innovator with a broadening neuropsych portfolio that should garner investors' interest as... More
